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Abstract
Background—Black men are disproportionately affected by both cardiovascular disease and 
prostate cancer. Epidemiologic evidence linking dyslipidemia, an established cardiovascular risk 
factor, and prostate cancer progression is mixed. As existing studies were conducted in 
predominantly non-black populations, research in black men is lacking.
Methods—We identified 628 black and 1,020 non-black men who underwent radical 
prostatectomy and never used statins before surgery in the Shared Equal Access Regional Cancer 
Hospital (SEARCH) database. Median follow up was 2.9 years. The impact of preoperative 
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hypercholesterolemia on risk of biochemical recurrence was examined using multivariable, race-
stratified proportional hazards. In secondary analysis, we examined associations with low-density 
lipoprotein (LDL), high-density lipoprotein (HDL) and triglycerides, overall and among men with 
dyslipidemia.
Results—High cholesterol was associated with increased risk of recurrence in black 
(HRper10mg/dl 1.06; 95%CI 1.02–1.11) but not non-black men (HRper10mg/dl 0.99; 95%CI 0.95–
1.03; p-interaction=0.011). Elevated triglycerides were associated with increased risk in both 
black and non-black men (HRper10mg/dl 1.02; 95%CI 1.00–1.03 and 1.02; 95%CI 1.00–1.02, 
respectively; p-interaction=0.458). There were no significant associations between LDL or HDL 
and recurrence risk in either race. Associations with cholesterol, LDL and triglycerides were 
similar among men with dyslipidemia, but low HDL was associated with increased risk of 
recurrence in black, but not non-black men with dyslipidemia (p-interaction=0.047).
Conclusion—Elevated cholesterol was a risk factor for recurrence in black but not non-black 
men, whereas high triglycerides were associated with increased risk regardless of race.
Impact—Significantly contrasting associations by race may provide insight into prostate cancer 
racial disparities.
Keywords
biochemical recurrence; black; cholesterol; dyslipidemia; high-density lipoprotein; lipids; low-
density lipoprotein; prostate cancer; race; triglycerides
Introduction
Relative to non-black men, black men are almost twice as likely to be diagnosed with 
prostate cancer, and more than twice as likely to die of their disease [1]. While non-biologic 
mechanisms such as access to care and socioeconomic status contribute to prostate cancer 
racial disparities [2], racial differences in host and tumor biology may also play a role [3].
Strong biologic rationale supports a role for cholesterol in prostate cancer pathogenesis via 
multiple mechanisms including Akt pathway activation [4] and intratumoral steroid 
biosynthesis [5], resulting in increased cellular proliferation and migration [6]. However, 
while some epidemiologic evidence supports a positive association between cholesterol and 
risk of aggressive prostate cancer [7–9], not all studies have reported this finding [10–13]. 
Similarly, the impact of hypercholesterolemia on prostate cancer recurrence and mortality is 
unclear. One prospective study reported that elevated cholesterol was associated with 
increased risk of prostate cancer-specific mortality [14], but other large prospective studies 
did not replicate this finding [15, 16]. However, these studies were conducted in 
predominantly non-black populations, and therefore the impact of race on associations 
between cholesterol and prostate cancer is unknown.
We examined the impact of preoperative serum lipid levels on risk of recurrence using a 
retrospective cohort of black and non-black prostate cancer patients who never used statins 
prior to radical prostatectomy from the Shared Equal Access Regional Cancer Hospital 
(SEARCH) database. Previously in this cohort, we reported that elevated triglycerides were 
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associated with increased risk of prostate cancer recurrence among all men, while high 
cholesterol, high low-density lipoprotein (LDL) and low high-density lipoprotein (HDL) 
were associated with increased risk of recurrence only among men with dyslipidemia [17]. 
However, due to limited numbers of patients in our prior study, we were unable to test 
whether associations differed between black and non-black men. Using an updated and 
larger cohort, the aim of the present analysis was to test for racial differences in the 
association between cholesterol and risk of prostate cancer recurrence. In secondary 
analysis, we explored associations between LDL, HDL and triglycerides and risk of prostate 
cancer recurrence in black and non-black men.
Materials and Methods
Study population
The SEARCH database is a retrospective cohort of prostate cancer patients undergoing 
radical prostatectomy at six Veterans Administration (VA) Medical Centers (West Los 
Angeles, CA; Palo Alto, CA; San Diego, CA; Durham, NC; Asheville, NC; and Augusta, 
GA) [17]. Institutional Review Board approval was obtained to abstract and analyze the 
data. SEARCH does not include patients treated with preoperative androgen deprivation or 
radiation therapy. Though data in SEARCH go back to 1988, preoperative cholesterol data 
were limited until 1999. Therefore, given that preoperative serum cholesterol level was our 
primary exposure of interest for the present analysis, we limited our analyses to men treated 
between 1999 and 2013 (n=3,553). As previously described [17], patients who used statins 
before surgery were excluded (n=920). We also excluded patients with missing data for any 
preoperative serum lipid levels (n=724), preoperative PSA (n=11), body mass index (BMI; 
n=107), pathologic Gleason score (n=12), other pathologic features (n=79) and PSA follow-
up (n=52). These exclusions resulted in a study population of 1,648 men, of which 628 were 
black and 1,020 were non-black (n=907 white and n=112 other race).
Exposure assessment
Fasting serum cholesterol, LDL, HDL and triglyceride levels, measured within the year prior 
to radical prostatectomy, were abstracted from VA computerized medical records. 
Recommended cut points for normal, borderline and high serum levels (all in mg/dl) of total 
cholesterol (<200, 200–239, ≥240), LDL (<130, 130–159, ≥160), HDL (<40, 40–59, ≥60) 
and triglycerides (<150, 150–199, ≥200) were selected according to National Cholesterol 
Education Program (NCEP)-Adult Treatment Panel (ATP) III guidelines [18]. As previously 
described [17], we defined dyslipidemia (abnormal/borderline vs. normal levels) for each 
individual lipid independently of the others.
Outcome assessment
Follow-up protocols were at the discretion of the treating physicians. Biochemical 
recurrence was defined as a single PSA >0.2 ng/ml, two consecutive concentrations at 0.2 
ng/ml, or secondary treatment for detectable postoperative PSA. Men receiving adjuvant 
therapy after surgery for an undetectable PSA were considered non-recurrent at the time of 
adjuvant therapy, and their follow-up was censored at that point.
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Statistical analysis
Differences in demographic, clinical and pathologic factors between black and non-black 
patients, overall and stratified by serum cholesterol level (<200, 200–239, ≥240 mg/dl) were 
examined using t-tests and χ2 tests for continuous and categorical variables, respectively, 
and rank-sum tests for continuous variables not normally distributed. Fisher’s exact test was 
used for categorical variables when there was a cell count <5. Differences in these factors 
between our cohort and men excluded from our analysis due to preoperative statin use 
(n=920) were also examined (Supplementary Table S1).
Cox proportional hazards analysis was used to examine the impact of hypercholesterolemia 
on risk of prostate cancer recurrence, stratified by race (black vs. non-black). We examined 
cholesterol levels both as categorical (<200 (reference), 200–239, ≥240 mg/dl) and 
continuous variables, with continuous cholesterol levels presented in 10 mg/dl increments to 
facilitate interpretation of the hazard ratios (HRs). Cox models were adjusted for age at 
surgery (continuous), preoperative PSA (continuous, log-transformed), year of surgery, 
preoperative BMI (continuous, log-transformed), pathologic Gleason score (2−6, 7 (3+4), 7 
(4+3)−10), positive surgical margins (yes vs. no), seminal vesicle invasion (yes vs. no), and 
surgical center. We also adjusted Cox models for postoperative statin use as a time-
dependent covariate, as described previously [17]. We tested for an interaction between 
serum cholesterol (continuous) and race in predicting risk of recurrence by incorporating a 
cross product term into our models.
In secondary analysis, we examined associations between LDL, HDL, triglycerides and risk 
of prostate cancer recurrence, stratified by race (black vs. non-black), using the same 
approach as described for cholesterol. In addition, given our previous findings that 
associations between serum lipids and risk of recurrence were stronger among men with 
dyslipidemia [17], we repeated all of our analyses among men with dyslipidemia, treating 
lipid levels as continuous variables. We conducted a sensitivity analysis by excluding men 
of other race (n=112). While cholesterol, LDL and HDL levels were normally distributed, 
the distribution of triglycerides was slightly skewed and so we performed a sensitivity 
analysis using log-transformed triglycerides. Given that this did not impact associations with 
recurrence, we present the results for untransformed triglycerides to facilitate the 
interpretation of our findings. We also explored the impact of excluding men with any 
outlying lipid value from our analysis, using the formula <Q1−1.5*IQR or >Q3+1.5*IQR to 
identify outliers. This resulted in the exclusion of 191 men, but as results were similar, these 
data are not presented. Finally, given the established link between dyslipidemia and 
increased risk of death from causes other than prostate cancer [19], we repeated our main 
analyses using competing risks regression, treating non-prostate cancer death as a competing 
risk for biochemical recurrence.
Statistical analysis was performed using Stata, version 13.0 (Stata Corp., College Station, 
TX, USA).
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Results
Patient and tumor characteristics by race
In our cohort of 628 (38%) black and 1,020 (62%) non-black men who never used statins 
prior to radical prostatectomy, black men were younger at surgery, but there were no 
differences in year of surgery or median follow-up by race (Table 1). Median PSA levels 
were higher in black men (6.6 vs. 6.2 ng/ml; p=0.001). While black men were more likely to 
have positive margins (p=0.003), there were no differences in rates of extracapsular 
extension, seminal vesicle invasion or lymph node status by race (Table 1). Black men had 
higher HDL but lower triglyceride levels than non-black men, but there were no differences 
in BMI, prevalence of diabetes, or mean levels of cholesterol or LDL by race. In this cohort 
of men who never used statins prior to radical prostatectomy, black and non-black men had 
similar rates of statin initiation after radical prostatectomy (19% and 18%, respectively; 
Table 1).
Patient and tumor characteristics by serum cholesterol level, stratified by race
The prevalence of hypercholesterolemia did not differ by race, with similar proportions of 
black and non-black men with borderline and high preoperative cholesterol. There were no 
differences in pathologic Gleason score, positive margin status, extracapsular extension, 
seminal vesicle invasion or lymph node status by cholesterol level in either race (Tables 2, 
3). While BMI and prevalence of diabetes did not differ by cholesterol level, men with high 
cholesterol had higher LDL, HDL and triglycerides than men with normal cholesterol, 
regardless of race (all p<0.001). Men with high cholesterol were more likely to initiate statin 
use after radical prostatectomy, regardless of race (p≤0.001, Tables 2, 3).
Associations between serum cholesterol and risk of recurrence
During a median follow-up period of 2.9 years (IQR 1.4–6.2 years), 181 (29%) black and 
272 (27%) non-black men experienced biochemical recurrence. After adjusting for 
demographic, clinical and pathologic characteristics, high cholesterol was associated with 
increased risk of recurrence in black men (≥240 vs. <200 mg/dl; HR 2.31; 95% CI 1.39–
3.86), with a 6% increased risk of recurrence for every 10 mg/dl increase in cholesterol 
(HRper 10 mg/dl 1.06; 95% CI 1.02–1.11; Table 4). In contrast, there was no association 
between cholesterol and risk of recurrence in non-black men, treating cholesterol either as a 
categorical (≥240 vs. <200 mg/dl; HR 1.17; 95% CI 0.71–1.92) or continuous variable 
(HRper 10 mg/dl 0.99; 95% CI 0.95–1.03). The interaction between race and cholesterol in 
predicting risk of recurrence was significant (p-interaction = 0.011). Excluding men of other 
race did not substantially impact our findings (Supplementary Table S2).
Associations between LDL, HDL and triglycerides and risk of recurrence
There was no significant association between HDL levels and risk of recurrence in either 
race, treating HDL either as a categorical or continuous variable. While there were no 
significant associations between LDL levels and risk of recurrence, there was a suggestion 
that elevated LDL was associated with increased risk of recurrence in black men 
(HRper 10 mg/dl 1.04; 95% CI 0.99–1.10; Table 4). Conversely, there was a suggestion of an 
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opposite direction of association in non-black men (HRper 10 mg/dl 0.98; 95% CI 0.94–1.02), 
with a significant interaction between race and LDL in association with risk of recurrence 
(p-interaction = 0.028).
Relative to normal triglyceride levels, elevated triglycerides were associated with increased 
risk of recurrence in black men (≥200 vs. <150 mg/dl; HR 1.75; 95% CI 1.22–2.52), with an 
attenuated but similar direction of association in non-black men (HR 1.27; 95% CI 0.94–
1.72; Table 4). Treating triglycerides as a continuous variable, each 10 mg/dl increase in 
triglycerides was accompanied by a 2% increased risk of recurrence in both black 
(HRper 10 mg/dl 1.02; 95% CI 1.00–1.03) and non-black men (HRper 10 mg/dl 1.02; 95% CI 
1.00–1.02), with no differences in these associations by race (p-interaction = 0.458).
Relative to normal lipid levels, there were no associations between borderline lipid levels in 
any lipid measure and risk of recurrence in either race (Table 4). Competing risk analysis 
did not substantially alter our findings (Supplementary Table S3).
Associations between serum lipids and risk of recurrence, among men with dyslipidemia
Restricting analyses to men with dyslipidemia produced similar findings to those reported 
among all men. There was a 22% increase in risk of recurrence for every 10 mg/dl increase 
in cholesterol above 200 mg/dl in black men (HR per 10 mg/dl 1.22; 95% CI 1.13–1.31), with 
no evidence for any association in non-black men (HR per 10 mg/dl 0.99; 95% CI 0.90–1.09; 
Table 4). The interaction between race and serum cholesterol for predicting recurrence in 
men with high cholesterol levels was significant (p-interaction = 0.001).
Whereas HDL was unrelated to recurrence risk among all men, when we restricted analysis 
to men with low HDL (<40 mg/dl), each 10 mg/dl increase in HDL was significantly 
associated with reduced risk of recurrence in black (HR per 10 mg/dl 0.40; 95% CI 0.23–0.70), 
but not non-black men (HR per 10 mg/dl 0.75, 95% CI 0.51–1.12). The interaction between 
race and HDL in predicting recurrence risk was significant (p-interaction = 0.047). While 
there were no significant associations between increasing LDL and risk of recurrence, the 
direction of the associations differed by race (suggestively positive in blacks but 
suggestively inverse in non-blacks), with a borderline significant interaction between race 
and LDL in predicting risk of recurrence in men with high LDL (p-interaction = 0.051).
Finally, similar to our findings among all men, each 10 mg/dl increase in triglycerides above 
150 mg/dl was associated with increased risk of recurrence in both black (HR per 10 mg/dl 
1.02; 95% CI 0.99–1.05) and non-black men (HR per 10 mg/dl 1.01; 95% CI 1.00–1.03; Table 
4), although these associations were slightly attenuated compared to our estimates among all 
men. There was no significant interaction between race and triglycerides (p-interaction = 
0.488).
Discussion
In this retrospective cohort of prostate cancer patients treated with radical prostatectomy, we 
show that the association between serum cholesterol and prostate cancer recurrence differed 
significantly by race, with hypercholesterolemia associated with increased risk of recurrence 
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in black, but not non-black men. In contrast, although LDL and HDL levels were not 
significantly associated with risk of prostate cancer recurrence, elevated triglycerides were 
associated with increased risk of recurrence regardless of race. Secondary analyses among 
men with dyslipidemia did not substantially impact associations between cholesterol, LDL 
or triglycerides and risk of recurrence, but revealed that low HDL was associated with 
increased risk of recurrence in black, but not non-black men with dyslipidemia. If 
confirmed, these findings suggest that hypercholesterolemia may disproportionately increase 
risk of prostate cancer recurrence in black men, thereby providing some mechanistic insight 
into prostate cancer racial disparities.
Previously, we reported null associations between cholesterol and its sub fractions, LDL and 
HDL, and risk of prostate cancer recurrence in a smaller subset of the present cohort which 
combined data from black and non-black men [17]. Given the smaller sample size, we were 
unable to test for interactions by race in this prior study. Few other studies have explored 
associations between lipid levels and risk of prostate cancer recurrence, with no consistent 
findings [13,20]. However, several large prospective studies in non-black populations have 
examined the association between dyslipidemia and prostate cancer-specific mortality. The 
UK Whitehall study, consisting of approximately 18,000 men and 600 prostate cancer 
deaths occurring during 40 years of follow up, reported that high cholesterol was associated 
with a modestly elevated risk of prostate cancer-specific mortality [14]. In contrast, the 
Metabolic Syndrome and Cancer Project, comprising almost 300,000 men from Northern 
Europe and over 1,000 prostate cancer deaths, reported similar rates of prostate cancer-
specific mortality in men with normal versus elevated triglyceride and cholesterol levels 
[15]. Finally, the findings of a large prospective study in the Asian-Pacific region were 
suggestive of a positive association between high cholesterol and increased prostate cancer-
specific mortality, though associations did not reach statistical significance [16]. Thus, 
although data are somewhat sparse and largely represent non-black men, together these 
findings suggest a weak to null association between dyslipidemia and prostate cancer 
recurrence and mortality. However, in the present analysis, we show that when stratified by 
race, hypercholesterolemia was associated with a significantly increased risk of prostate 
cancer recurrence in black but not non-black men. Our null results in non-black men are 
consistent with previous studies in non-black populations, which also reported largely null 
findings. However, our positive findings among black men may provide rationale for future 
studies to explore racial differences in these associations.
Despite lower rates of visceral obesity [21, 22], and a more favorable lipid profile (including 
lower triglycerides [23] and higher HDL [24]), the prevalence of cardiovascular disease is 
higher in black, relative to non-black populations [25, 26]. However, while many 
cardiovascular risk factors have also been implicated in prostate cancer pathogenesis [27], 
racial differences in associations between obesity, dyslipidemia and prostate cancer 
progression have not been widely explored. In addition to evidence from the present analysis 
that the association between cholesterol and prostate cancer recurrence varies by race, on 
secondary analysis we also observed a suggestion of racial differences in associations 
between cholesterol sub-fractions, LDL and HDL, and risk of recurrence. To our 
knowledge, no studies have examined racial differences in associations between lipid levels 
and prostate cancer recurrence. However, one prior study reported that high LDL levels 
Allott et al. Page 7
Cancer Epidemiol Biomarkers Prev. Author manuscript; available in PMC 2017 March 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
were associated with increased risk of prostate cancer on biopsy in black, but not non-black 
men [28], while a case-control study reported racial differences in the association between 
metabolic syndrome, a cluster of conditions including low HDL and high triglyceride levels, 
and prostate cancer risk [29]. In the present study, while associations between LDL and risk 
of recurrence were not significant in either race, the directions of association were 
significantly contrasting, with LDL showing a positive association with recurrence in blacks, 
but an inverse association in non-blacks. Finally, we found that each 10 mg/dl increase in 
HDL levels among men with low HDL was significantly protective in black, but not non-
black men. While future studies are required to validate these results, our findings of racial 
differences in the association between dyslipidemia and prostate cancer recurrence, in 
particular our primary findings for cholesterol which showed a strong racial interaction 
(p=0.001), suggest that dyslipidemia may be a mechanism contributing to racial disparities 
in prostate cancer.
Our findings should be considered in light of the study’s strengths and limitations. First, 
serum lipid measurements were obtained in the year prior to radical prostatectomy and 
therefore may be impacted by the presence of preclinical disease [30]. However, the 
presence of preclinical disease would be expected to lower serum lipid levels [31], thereby 
biases our estimates towards the null. As such, our analyses may have underestimated the 
strength of the association between serum lipid levels and reduced risk of recurrence. 
Furthermore, bias due to reverse causation is less likely in screened populations such as ours 
where prostate cancer is diagnosed early in the natural history of the disease. Indeed, in our 
prior study in a subset of the current patient cohort, we tested the impact of excluding 
recurrence events within one year of diagnosis and found that this did not alter our findings 
[17]. Second, given that we lacked sufficient numbers of events to explore racial differences 
in the association between dyslipidemia and prostate cancer-specific mortality, we examined 
biochemical recurrence as a surrogate endpoint. While time to biochemical recurrence is 
informative for predicting risk of prostate cancer-specific mortality, the natural history of 
prostate cancer following biochemical recurrence can vary greatly between individuals [32]. 
Therefore, studies with longer follow up are required to assess the impact of dyslipidemia on 
longer-term prostate cancer outcomes. Third, we did not adjust for multiple testing, and so 
our findings from secondary analyses of associations between triglycerides, LDL and HDL 
and risk of recurrence should be interpreted with caution. Finally, we made two main sets of 
exclusions in this manuscript: patients with missing lipid levels and patients who used 
statins prior to surgery. We previously showed that demographic, clinical and pathologic 
features of patients with missing lipid levels did not differ from those without missing lipid 
data [17]. Therefore, our missing lipid data appear to be missing at random, thereby 
alleviating concerns about selection bias. We acknowledge that excluding patients who used 
statins prior to surgery likely truncates our range of exposure by excluding many patients 
with high cholesterol from our analysis, thereby potentially introducing bias into our study. 
However, we argue that exclusion of preoperative statin users from our analysis strengthens 
our exposure assessment for the following reasons. First, date of preoperative statin 
initiation and duration of preoperative statin use are not available in this dataset. As such, we 
do not have access to data that would be informative in our efforts to adjust lipid levels to 
account for preoperative statin use. Second, inter-individual variability in the degree to 
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which statins lower lipid levels further hampers our ability to select a constant value to add 
to the lipid levels of preoperative statin users. Finally, the “window of susceptibility” for 
serum lipids to impact PC recurrence is unknown. As such, we don’t know whether lipid 
levels are most relevant at the time of tumor initiation or at the time of diagnosis when the 
tumor comes to clinical attention. Given that we only know statin use status at the time of 
diagnosis and not before, it may be inappropriate to add a constant value to lipid levels of 
statin users if their tumor developed in a lower lipid environment (i.e. if the patient was a 
long term statin user). For these reasons, we believe that adjusting lipid levels to account for 
preoperative statin use would lead to uncertainty in the accuracy of our lipid data, and we 
decided instead to exclude preoperative statin users. As shown in Supplementary Table S1, 
men excluded from our analysis due to preoperative statin use were older at diagnosis and 
less likely to be black. Preoperative statin users had lower PSA and lower pathologic 
Gleason score, but there were no differences in other pathologic features between 
preoperative statin users and nonusers. While cholesterol or LDL levels did not differ, 
preoperative statin users had higher BMI, higher prevalence of diabetes, lower HDL and 
higher triglycerides, relative to nonusers. Given these differences between the characteristics 
of preoperative statin users and those of our cohort, the exclusion of these patients may have 
given rise to selection bias and may limit the generalizability of our findings. However, the 
exclusion of men using statins prior to radical prostatectomy strengthens our exposure 
assessment by ensuring that our assessment of preoperative serum lipid levels was 
unaffected by statin use. Furthermore, we adjusted our models for postoperative statin use as 
a time-dependent covariate, enabling us to account for varying start dates and duration of 
statin use during the follow-up period. Finally, SEARCH represents a racially diverse 
sample population and enables examination of biologic contributors to prostate cancer racial 
disparities in the context of equal access to care.
In summary, hypercholesterolemia was associated with increased risk of recurrence in black, 
but not non-black men, while elevated triglycerides were associated with increased risk of 
prostate cancer recurrence regardless of race. Significantly contrasting associations by race 
may provide some mechanistic insight into prostate cancer racial disparities, and should be 
explored in future studies. Given that hypercholesterolemia may be a shared risk factor for 
cardiovascular disease and prostate cancer, two common causes of mortality in prostate 
cancer patients, understanding the mechanisms linking cholesterol and prostate cancer 
progression has high clinical and public health relevance.
Supplementary Material
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